Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer

Annals of Oncology

Volumn 19, Issue 11, 2008, Pages 1870-1874

  Suijkerbuijk, K P M ^a   Fackler, M J ^b   Sukumar, S ^b   Van gils, C H ^a   Van laar, T ^a   Van der wall, E ^a   Vooijs, M ^a   Van Diest, P J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

BRCA1; Breast cancer; Hereditary; Methylation; QM MSP

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYSTEINE RICH PROTEIN D2; ESTROGEN RECEPTOR 1; PROTEIN RARB; PROTEIN SCGB3A1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1; TRANSCRIPTION FACTOR TWIST 1; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; RISK FACTOR;

EID: 54949134514     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn409     Document Type: Article

References (29)

1. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004; 6: 229-239.
2. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
3. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408.
4. Brekelmans CTM, Seynaeve C, Bartels CCM et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001; 19: 924-930.
5. Kriege M, Brekelmans CT, Obdeijn IM et al. Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. Breast Cancer Res Treat 2006; 100: 109-119.
6. Steenman MJ, Rainier S, Dobry CJ et al. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genet 1994; 7: 433-439.
7. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003; 4: 351-358.
8. Herman JG, Baylin SB, Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-2054.
9. Ehrlich M. DNA methylation in cancer: Too much, but also too little. Oncogene 2002; 21: 5400-5413.
10. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet 2000; 16: 168-174.
11. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001; 1: 157-162.
12. van Diest PJ. Ductal carcinoma in situ In breast carcinogenesis. J Pathol 1999; 187: 383-384.
13. Lee JS. GSTP1 promoter hypermethylation is an early event in breast carcinogenesis. Virchows Arch 2007; 450: 637-642.
14. Deshmane VH, Fentiman IS, Hart IR. Early detection of malignant change in breast cells. Lancet 2001; 358: 507.
15. Fackler MJ, Malone K, Zhang Z et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 2006; 12: 3306-3310.
16. Fackler W, McVeigh M, Mehrotra J et al. Quarrtitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004; 64: 4442-4452.
17. Trinh BN, Long TI, Nickel AE et al. DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair. Mol Cell Biol 2002; 22: 2906-2917.
18. Ahuja N, Mohan AL, Li Q et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res 1997; 57: 3370-3374.
19. Caldeira JR, Prando EC, Quevedo FC et al. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer 2006; 6: 48.
20. Archey WB, McEachem KA, Robson M et al. Increased CpG methylation of the estrogen receptor gene In BRCA1-linked estrogen receptor-negative breast cancers. Oncogene 2002; 21: 7034-7041.
21. van Diest PJ. No consent should be needed for using leftover body material for scientific purposes. Br Med J 2002; 325: 648-651.
22. van Diest PJ, Baak JP, Matze-Cok P et al. Reproducibility of mitosis counting in 2,469 breast cancer specimens: Results from the multicenter morphometric mammary carcinoma project. Hum Pathol 1992; 23: 603-607.
23. Haybittle JL, Blamey RW, Elston CW et al. A prognostic index in primary breast cancer. Br J Cancer 1982; 45: 361-366.
24. Korsching E, Packelsen J, Agelopoulos K et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: Integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002; 82: 1525-1533.
25. Esteller M, Fraga MF, Guo M et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001; 10: 3001-3007.
26. Tirkkonen M, Johannsson O, Agnarsson BA et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997; 57: 1222-1227.
27. Jonsson G, Naylor TL, Vallon-Christersson J et al. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 2005; 65: 7612-7621.
28. Ahuja N, Li Q, Mohan AL et al. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998; 58: 5489-5494.
29. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002; 21: 5462-5482.